Learn more →
Back to Expert Scholars
melanoma / melanomaMelanoma Immunotherapy

Reinhard Dummer

莱因哈德·杜默

MD

🏢University Hospital Zurich(苏黎世大学医院)🌐Switzerland

Professor and Head, Department of Dermatology皮肤科教授兼主任

80
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Reinhard Dummer is a Swiss dermatologist-oncologist and global authority on melanoma biology and targeted therapy. He has led landmark trials of BRAF/MEK inhibitors including encorafenib-binimetinib and contributed substantially to understanding melanoma genomics and resistance.

Share:

🧪Research Fields 研究领域

Melanoma黑色素瘤
BRAF V600 Targeted TherapyBRAF V600靶向治疗
Melanoma Biology黑色素瘤生物学
Combination Targeted Therapy联合靶向治疗

🎓Key Contributions 主要贡献

Encorafenib-Binimetinib Combination

Led COLUMBUS trial establishing encorafenib plus binimetinib as superior to vemurafenib and other BRAF inhibitor regimens in BRAF V600-mutant melanoma, with improved tolerability.

Melanoma Genomics

Advanced understanding of oncogenic drivers and co-mutations in melanoma, identifying predictive biomarkers for targeted therapy response and informing precision oncology strategies.

Resistance to BRAF Inhibitors

Characterized molecular mechanisms of acquired resistance to BRAF inhibitors, leading to rational combinatorial approaches that delay resistance and improve durability of response.

Representative Works 代表性著作

[1]

Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS)

The Lancet Oncology (2018)

Demonstrated superior PFS and OS with encorafenib-binimetinib, establishing a new BRAF/MEK inhibitor standard.

[2]

Pembrolizumab versus Ipilimumab for Advanced Melanoma: Final Overall Survival Results of a Randomized Trial

Journal of Clinical Oncology (2021)

Long-term survival analysis confirming pembrolizumab's sustained OS advantage over ipilimumab.

[3]

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

New England Journal of Medicine (2014)

Demonstrated activity of BRAF inhibition across multiple BRAF V600-mutant tumor types beyond melanoma.

🏆Awards & Recognition 奖项与荣誉

🏆European Society for Dermatological Oncology (ESDO) Award
🏆Swiss Cancer League Research Prize
🏆EADO Merit Award
🏆International League of Dermatological Societies Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 莱因哈德·杜默 的研究动态

Follow Reinhard Dummer's research updates

留下邮箱,当我们发布与 Reinhard Dummer(University Hospital Zurich)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment